Efficacy and safety of trastuzumab deruxtecan in Chinese patients with HER2-positive and HER2-low advanced breast cancer: a multicenter, observational, real-world study
Objective: Limited real-world efficacy and safety data exist regarding the use of trastuzumab deruxtecan (T-DXd) in the Chinese population with human epidermal growth factor receptor (HER2)-positive and HER2-low advanced breast cancer (BC). This multicenter, observational, real-world study aimed to...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-02-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359251318853 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849764410696925184 |
|---|---|
| author | Die Sang Yanfang Su Yurong Zhang Yanfeng Guan Shanmin Fan Jintao Zhang Lijun Zheng Yanling Wang Ying Guo Zixuan Lei Man Li Peng Yuan |
| author_facet | Die Sang Yanfang Su Yurong Zhang Yanfeng Guan Shanmin Fan Jintao Zhang Lijun Zheng Yanling Wang Ying Guo Zixuan Lei Man Li Peng Yuan |
| author_sort | Die Sang |
| collection | DOAJ |
| description | Objective: Limited real-world efficacy and safety data exist regarding the use of trastuzumab deruxtecan (T-DXd) in the Chinese population with human epidermal growth factor receptor (HER2)-positive and HER2-low advanced breast cancer (BC). This multicenter, observational, real-world study aimed to evaluate the efficacy and safety of T-DXd for the treatment of Chinese patients with HER2-positive and HER2-low advanced BC. Methods: The medical records of 61 patients were collected from The Second Hospital of Dalian Medical University, Beijing Chaoyang District Sanhuan Cancer Hospital, Beijing Jingxin Hospital, and Cancer Hospital of the Chinese Academy of Medical Sciences. The primary endpoint of the study was progression-free survival (PFS), and the secondary endpoints were overall survival (OS), objective response rate (ORR), disease control rate (DCR), time to response (TTR), and safety. PFS and OS were analyzed using the Kaplan–Meier method and log-rank test. Results: The primary endpoint, PFS was 10.51 months (95% confidence interval (CI), 3.02–NE) in the HER2-low group and 10.18 months (95% CI, 3.88–NE) in the HER2-positive group. Regarding the secondary endpoints in the HER2-low and HER2-positive groups, OS data were immature, ORR rates were 37.93% and 62.50%, DCR rates were 79.31% and 87.50%, and the median TTR rates were 1.28 and 1.31 months, respectively. In the subgroup analysis, front-line treatment with T-DXd was associated with increased beneficial effects. The primary adverse events (AEs) related to T-DXd treatment were gastrointestinal reactions and bone marrow suppression, which were predominantly grades 1–2, with no severe grade 4/5 AEs reported, only one patient developed infectious pneumonia. Conclusion: This study was the first multicenter, real-world study of T-DXd for advanced BC in China. The findings demonstrated that T-DXd may be an effective antitumor treatment with controllable adverse reactions in patients with advanced BC irrespective of HER2 expression levels. |
| format | Article |
| id | doaj-art-1660ba6601e843cfbdea55dc7685a5a3 |
| institution | DOAJ |
| issn | 1758-8359 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj-art-1660ba6601e843cfbdea55dc7685a5a32025-08-20T03:05:09ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592025-02-011710.1177/17588359251318853Efficacy and safety of trastuzumab deruxtecan in Chinese patients with HER2-positive and HER2-low advanced breast cancer: a multicenter, observational, real-world studyDie SangYanfang SuYurong ZhangYanfeng GuanShanmin FanJintao ZhangLijun ZhengYanling WangYing GuoZixuan LeiMan LiPeng YuanObjective: Limited real-world efficacy and safety data exist regarding the use of trastuzumab deruxtecan (T-DXd) in the Chinese population with human epidermal growth factor receptor (HER2)-positive and HER2-low advanced breast cancer (BC). This multicenter, observational, real-world study aimed to evaluate the efficacy and safety of T-DXd for the treatment of Chinese patients with HER2-positive and HER2-low advanced BC. Methods: The medical records of 61 patients were collected from The Second Hospital of Dalian Medical University, Beijing Chaoyang District Sanhuan Cancer Hospital, Beijing Jingxin Hospital, and Cancer Hospital of the Chinese Academy of Medical Sciences. The primary endpoint of the study was progression-free survival (PFS), and the secondary endpoints were overall survival (OS), objective response rate (ORR), disease control rate (DCR), time to response (TTR), and safety. PFS and OS were analyzed using the Kaplan–Meier method and log-rank test. Results: The primary endpoint, PFS was 10.51 months (95% confidence interval (CI), 3.02–NE) in the HER2-low group and 10.18 months (95% CI, 3.88–NE) in the HER2-positive group. Regarding the secondary endpoints in the HER2-low and HER2-positive groups, OS data were immature, ORR rates were 37.93% and 62.50%, DCR rates were 79.31% and 87.50%, and the median TTR rates were 1.28 and 1.31 months, respectively. In the subgroup analysis, front-line treatment with T-DXd was associated with increased beneficial effects. The primary adverse events (AEs) related to T-DXd treatment were gastrointestinal reactions and bone marrow suppression, which were predominantly grades 1–2, with no severe grade 4/5 AEs reported, only one patient developed infectious pneumonia. Conclusion: This study was the first multicenter, real-world study of T-DXd for advanced BC in China. The findings demonstrated that T-DXd may be an effective antitumor treatment with controllable adverse reactions in patients with advanced BC irrespective of HER2 expression levels.https://doi.org/10.1177/17588359251318853 |
| spellingShingle | Die Sang Yanfang Su Yurong Zhang Yanfeng Guan Shanmin Fan Jintao Zhang Lijun Zheng Yanling Wang Ying Guo Zixuan Lei Man Li Peng Yuan Efficacy and safety of trastuzumab deruxtecan in Chinese patients with HER2-positive and HER2-low advanced breast cancer: a multicenter, observational, real-world study Therapeutic Advances in Medical Oncology |
| title | Efficacy and safety of trastuzumab deruxtecan in Chinese patients with HER2-positive and HER2-low advanced breast cancer: a multicenter, observational, real-world study |
| title_full | Efficacy and safety of trastuzumab deruxtecan in Chinese patients with HER2-positive and HER2-low advanced breast cancer: a multicenter, observational, real-world study |
| title_fullStr | Efficacy and safety of trastuzumab deruxtecan in Chinese patients with HER2-positive and HER2-low advanced breast cancer: a multicenter, observational, real-world study |
| title_full_unstemmed | Efficacy and safety of trastuzumab deruxtecan in Chinese patients with HER2-positive and HER2-low advanced breast cancer: a multicenter, observational, real-world study |
| title_short | Efficacy and safety of trastuzumab deruxtecan in Chinese patients with HER2-positive and HER2-low advanced breast cancer: a multicenter, observational, real-world study |
| title_sort | efficacy and safety of trastuzumab deruxtecan in chinese patients with her2 positive and her2 low advanced breast cancer a multicenter observational real world study |
| url | https://doi.org/10.1177/17588359251318853 |
| work_keys_str_mv | AT diesang efficacyandsafetyoftrastuzumabderuxtecaninchinesepatientswithher2positiveandher2lowadvancedbreastcanceramulticenterobservationalrealworldstudy AT yanfangsu efficacyandsafetyoftrastuzumabderuxtecaninchinesepatientswithher2positiveandher2lowadvancedbreastcanceramulticenterobservationalrealworldstudy AT yurongzhang efficacyandsafetyoftrastuzumabderuxtecaninchinesepatientswithher2positiveandher2lowadvancedbreastcanceramulticenterobservationalrealworldstudy AT yanfengguan efficacyandsafetyoftrastuzumabderuxtecaninchinesepatientswithher2positiveandher2lowadvancedbreastcanceramulticenterobservationalrealworldstudy AT shanminfan efficacyandsafetyoftrastuzumabderuxtecaninchinesepatientswithher2positiveandher2lowadvancedbreastcanceramulticenterobservationalrealworldstudy AT jintaozhang efficacyandsafetyoftrastuzumabderuxtecaninchinesepatientswithher2positiveandher2lowadvancedbreastcanceramulticenterobservationalrealworldstudy AT lijunzheng efficacyandsafetyoftrastuzumabderuxtecaninchinesepatientswithher2positiveandher2lowadvancedbreastcanceramulticenterobservationalrealworldstudy AT yanlingwang efficacyandsafetyoftrastuzumabderuxtecaninchinesepatientswithher2positiveandher2lowadvancedbreastcanceramulticenterobservationalrealworldstudy AT yingguo efficacyandsafetyoftrastuzumabderuxtecaninchinesepatientswithher2positiveandher2lowadvancedbreastcanceramulticenterobservationalrealworldstudy AT zixuanlei efficacyandsafetyoftrastuzumabderuxtecaninchinesepatientswithher2positiveandher2lowadvancedbreastcanceramulticenterobservationalrealworldstudy AT manli efficacyandsafetyoftrastuzumabderuxtecaninchinesepatientswithher2positiveandher2lowadvancedbreastcanceramulticenterobservationalrealworldstudy AT pengyuan efficacyandsafetyoftrastuzumabderuxtecaninchinesepatientswithher2positiveandher2lowadvancedbreastcanceramulticenterobservationalrealworldstudy |